109,812,253 Common Stock of Instil Bio, Inc. are subject to a Lock-Up Agreement Ending on 15-SEP-2021.
September 14, 2021
Share
109,812,253 Common Stock of Instil Bio, Inc. are subject to a Lock-Up Agreement Ending on 15-SEP-2021. These Common Stock will be under lockup for 181 days starting from 18-MAR-2021 to 15-SEP-2021.
Details:
All of the directors and officers and the holders of substantially all of outstanding stock and stock options have agreed that they will not offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock for a period ending 180 days after the date of the prospectus without the prior written consent of Morgan Stanley & Co. LLC, Jefferies LLC and Cowen and Company, LLC on behalf of the underwriters.
Instil Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte (TIL), therapies for the treatment of patients with cancer. It is developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor (CoStAR), platform. The Company's lead CoStAR-TIL product candidate, ITIL-306, expresses a CoStAR molecule designed to recognize folate receptor alpha (Fra), a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC and renal cancer. CAR-T and TCR-T therapies are cell products composed of T cells that have been genetically engineered to recognize a specific cancer-related antigen on the surface of tumor cells.
INSTIL BIO, INC. 
